The '''FinnProstate Group''' ('''FP'''), or '''FinnProstate Study Group''', is a group of [[scientific researcher]]s in [[Finland]] who have conducted a series of [[clinical trial]]s of treatments for [[prostate cancer]].<ref name="EmmansDeanNorman2006">{{citation | vauthors = Emmans Dean M, Norman G, Hodges Z, Ritchie G, Light K, Eastwood A, Langley R, Sydes M, Parmar M, Abel P | title = Parenteral Oestrogens for Prostate Cancer: A Systematic Review of Clinical Effectiveness and Dose Response (CRD Report 33) | year = 2006 | place = York | publisher = Centre for Reviews and Dissemination/University of York/York Publishing Services | isbn = 1900640376 | url = https://www.york.ac.uk/media/crd/crdreport33.pdf| archive-url = https://web.archive.org/web/20210908021015/https://www.york.ac.uk/media/crd/crdreport33.pdf | archive-date = 2021-09-08 }}</ref> The first publication by the group was in 1985<ref name="pmid4096480">{{cite journal | vauthors = Haapiainen R, Rannikko S, Ruutu M, Ala-Opas M, Aro J, Ervasti J, Hansson E, Hurme K, Juusela H, Mäkinen J | title = Early results of the Finnish Multicentre Study of Prostatic Cancer (Finnprostate) | journal = Ann Chir Gynaecol | volume = 74 | issue = 6 | pages = 277–83 | date = 1985 | pmid = 4096480 | doi = | url = }}</ref> and the latest publication was in 2019.<ref name="pmid31375279">{{cite journal | vauthors = Hackman G, Taari K, Tammela TL, Matikainen M, Kouri M, Joensuu T, Luukkaala T, Salonen A, Isotalo T, Pétas A, Hendolin N, Boström PJ, Aaltomaa S, Lehtoranta K, Hellström P, Riikonen J, Korpela M, Minn H, Kellokumpu-Lehtinen PL, Pukkala E, Hemminki A | title = Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension | journal = Eur Urol | volume = 76 | issue = 5 | pages = 586–595 | date = November 2019 | pmid = 31375279 | doi = 10.1016/j.eururo.2019.07.001 | hdl = 10138/306830 | s2cid = 199389424 | url = | hdl-access = free }}</ref>

==Clinical trials==
The studies conducted by the FinnProstate group include the following:<ref name="EmmansDeanNorman2006" />

* FinnProstate-1 (FinnProstate-I; Finnish Multicentre Study of Prostatic Cancer) – [[ethinylestradiol]] 150&nbsp;μg/day (1&nbsp;mg/day initially) plus [[polyestradiol phosphate]] 80&nbsp;mg/month (160&nbsp;mg/month initially) versus [[orchiectomy]] for [[advanced prostate cancer]]<ref name="pmid4096480">{{cite journal | vauthors = Haapiainen R, Rannikko S, Ruutu M, Ala-Opas M, Aro J, Ervasti J, Hansson E, Hurme K, Juusela H, Mäkinen J | title = Early results of the Finnish Multicentre Study of Prostatic Cancer (Finnprostate) | journal = Ann Chir Gynaecol | volume = 74 | issue = 6 | pages = 277–83 | date = 1985 | pmid = 4096480 | doi = | url = }}</ref><ref name="HaapiainenRannikkoAlfthan1986">{{cite journal | vauthors = Haapiainen R, Rannikko S, Alfthan O | date = April 1986 | title = Comparison of primary orchiectomy and estrogen therapy in advanced prostatic cancer - a 2 years follow-up | journal = Journal of Urology | volume = 135 | number = 4 | pages = A339 | url = https://scholar.google.com/scholar?cluster=1823112295528156833}}</ref><ref name="pmid3779355">{{cite journal | vauthors = Haapiainen R, Rannikko S, Alfthan O | title = Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective prostatic cancer study | journal = Br J Urol | volume = 58 | issue = 5 | pages = 528–33 | date = October 1986 | pmid = 3779355 | doi = 10.1111/j.1464-410x.1986.tb05461.x | url = }}</ref>
* FinnProstate-2 (FinnProstate-II) – [[polyestradiol phosphate]] 160&nbsp;mg/month (with or without low-dose [[aspirin]]) versus [[orchiectomy]] for [[advanced prostate cancer]]<ref name="pmid2659136">{{cite journal | vauthors = Aro JL, Haapiainen RK, Rannikko SA, Alfthan OS | title = High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group | journal = Br J Urol | volume = 63 | issue = 5 | pages = 512–4 | date = May 1989 | pmid = 2659136 | doi = 10.1111/j.1464-410x.1989.tb05946.x | url = }}</ref><ref name="pmid2132303">{{cite journal | vauthors = Haapiainen R, Rannikko S, Alfthan O | title = Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. Finnprostate Group | journal = Br J Urol | volume = 66 | issue = 1 | pages = 94–7 | date = July 1990 | pmid = 2132303 | doi = 10.1111/j.1464-410x.1990.tb14872.x | url = }}</ref>
* FinnProstate-3 (FinnProstate-III) – cancelled
* FinnProstate-4 (FinnProstate-IV) – [[polyestradiol phosphate]] 160&nbsp;mg/month versus [[buserelin]] (with [[cyproterone acetate]] 300&nbsp;mg/day initially to prevent [[gonadotropin]] flare) in [[advanced prostate cancer|advanced]] or [[metastatic prostate cancer]]<ref name="pmid8291869">{{cite journal | vauthors = Aro J, Ruutu M, Juusela H, Hansson E, Permi J | title = Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group | journal = Ann Chir Gynaecol Suppl | volume = 206 | issue = | pages = 5–8 | date = 1993 | pmid = 8291869 | doi = | url = }}</ref>
* FinnProstate-5 (FinnProstate-V) – cancelled
* FinnProstate-6 (FinnProstate-VI) – [[polyestradiol phosphate]] 240&nbsp;month (320&nbsp;mg/month initially) versus [[orchiectomy]] for [[advanced prostate cancer]]<ref name="pmid9698663">{{cite journal | vauthors = Mikkola AK, Ruutu ML, Aro JL, Rannikko SA, Salo JO | title = Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group | journal = Br J Urol | volume = 82 | issue = 1 | pages = 63–8 | date = July 1998 | pmid = 9698663 | doi = 10.1046/j.1464-410x.1998.00688.x | url = }}</ref><ref name="pmid16261661">{{cite journal | vauthors = Mikkola A, Aro J, Rannikko S, Oksanen H, Ruutu M | title = Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate | journal = Scand J Urol Nephrol | volume = 39 | issue = 4 | pages = 294–300 | date = 2005 | pmid = 16261661 | doi = 10.1080/00365590510031228 | s2cid = 24752258 | url = }}</ref><ref name="pmid17219379">{{cite journal | vauthors = Mikkola A, Aro J, Rannikko S, Ruutu M | title = Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy | journal = Prostate | volume = 67 | issue = 4 | pages = 447–55 | date = March 2007 | pmid = 17219379 | doi = 10.1002/pros.20547 | s2cid = 20549248 | url = }}</ref><ref name="pmid18070186">{{cite journal | vauthors = Mikkola AK, Aro JL, Rannikko AS, Ruutu ML | title = A high pretreatment plasma oestradiol level is associated with a low risk of acute myocardial infarction in parenteral oestrogen therapy for locally advanced prostate cancer | journal = BJU Int | volume = 101 | issue = 9 | pages = 1090–5 | date = May 2008 | pmid = 18070186 | doi = 10.1111/j.1464-410X.2007.07361.x | s2cid = 2843818 | url = | doi-access = free }}</ref><ref name="pmid19382005">{{cite journal | vauthors = Mikkola A, Aro J, Rannikko S, Ruutu M | title = Prognostic grouping of metastatic prostate cancer using conventional pretreatment prognostic factors | journal = Scand J Urol Nephrol | volume = 43 | issue = 4 | pages = 265–70 | date = 2009 | pmid = 19382005 | doi = 10.1080/00365590902836500 | s2cid = 24321902 | url = }}</ref><ref name="pmid10334106">{{cite journal | vauthors = Mikkola AK, Aro JL, Rannikko SA, Salo JO | title = Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer. FINNPROSTATE Group | journal = Prostate | volume = 39 | issue = 3 | pages = 175–81 | date = May 1999 | pmid = 10334106 | doi = 10.1002/(sici)1097-0045(19990515)39:3<175::aid-pros5>3.0.co;2-e | s2cid = 38212069 | url = }}</ref>
* FinnProstate-7 (FinnProstate-VII) – intermittent versus continuous [[androgen deprivation therapy]] for [[advanced prostate cancer]]<ref name="pmid22498230">{{cite journal | vauthors = Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL | title = The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer | journal = J Urol | volume = 187 | issue = 6 | pages = 2074–81 | date = June 2012 | pmid = 22498230 | doi = 10.1016/j.juro.2012.01.122 | url = }}</ref><ref name="pmid22857983">{{cite journal | vauthors = Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL | title = Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects | journal = Eur Urol | volume = 63 | issue = 1 | pages = 111–20 | date = January 2013 | pmid = 22857983 | doi = 10.1016/j.eururo.2012.07.040 | url = }}</ref><ref name="pmid24679247">{{cite journal | vauthors = Salonen AJ, Taari K, Ala-Opas M, Sankila A, Viitanen J, Lundstedt S, Tammela TL | title = Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII | journal = Scand J Urol | volume = 48 | issue = 6 | pages = 513–22 | date = December 2014 | pmid = 24679247 | doi = 10.3109/21681805.2014.901410 | s2cid = 24864704 | url = }}</ref>
* Other studies by the FinnProstate group<ref name="pmid2006119">{{cite journal | vauthors = Aro J | title = Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population | journal = Prostate | volume = 18 | issue = 2 | pages = 131–7 | date = 1991 | pmid = 2006119 | doi = 10.1002/pros.2990180205 | s2cid = 27915767 | url = }}</ref><ref name="pmid31375279">{{cite journal | vauthors = Hackman G, Taari K, Tammela TL, Matikainen M, Kouri M, Joensuu T, Luukkaala T, Salonen A, Isotalo T, Pétas A, Hendolin N, Boström PJ, Aaltomaa S, Lehtoranta K, Hellström P, Riikonen J, Korpela M, Minn H, Kellokumpu-Lehtinen PL, Pukkala E, Hemminki A | title = Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension | journal = Eur Urol | volume = 76 | issue = 5 | pages = 586–595 | date = November 2019 | pmid = 31375279 | doi = 10.1016/j.eururo.2019.07.001 | hdl = 10138/306830 | s2cid = 199389424 | url = | hdl-access = free }}</ref>

===Related trials===
A related study, by the Finnish Zoladex Multicentre Study Group, assessed polyestradiol phosphate versus [[goserelin]] for advanced prostate cancer.<ref name="EmmansDeanNorman2006" /><ref name="pmid7939468">{{cite journal | vauthors = Lukkarinen O, Kontturi M | title = Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma. An open prospective, randomized multicentre study | journal = Scand J Urol Nephrol | volume = 28 | issue = 2 | pages = 171–8 | date = June 1994 | pmid = 7939468 | doi = 10.3109/00365599409180495 | url = }}</ref> A [[British people|British]] group also assessed polyestradiol phosphate 160&nbsp;mg/month versus orchiectomy for advanced prostate cancer.<ref name="EmmansDeanNorman2006" /><ref name="pmid2679960">{{cite journal | vauthors = Bishop MC, Lemberger RJ, Selby C, Lawrence WT | title = Oestrogen dosage in prostatic cancer: the threshold effect? | journal = Br J Urol | volume = 64 | issue = 3 | pages = 290–6 | date = September 1989 | pmid = 2679960 | doi = 10.1111/j.1464-410x.1989.tb06016.x | url = }}</ref> The [[SPCG-5]] trial assessed [[polyestradiol phosphate]] 240&nbsp;mg/month versus combined androgen blockade ([[triptorelin]] or [[orchiectomy]] plus [[flutamide]]) for advanced prostate cancer.<ref name="EmmansDeanNorman2006" /><ref name="pmid10699602">{{cite journal | vauthors = Hedlund PO, Henriksson P | title = Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study | journal = Urology | volume = 55 | issue = 3 | pages = 328–33 | date = March 2000 | pmid = 10699602 | doi = 10.1016/s0090-4295(99)00580-4 | url = }}</ref><ref name="pmid12623503">{{cite journal | vauthors = Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette A, Rasmussen F, Salo J, Vaage S, Varenhorst E | title = Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5 | journal = Scand J Urol Nephrol | volume = 36 | issue = 6 | pages = 405–13 | date = 2002 | pmid = 12623503 | doi = 10.1080/003655902762467549 | s2cid = 2799580 | url = }}</ref><ref name="pmid18432528">{{cite journal | vauthors = Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J | title = Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5 | journal = Scand J Urol Nephrol | volume = 42 | issue = 3 | pages = 220–9 | date = 2008 | pmid = 18432528 | doi = 10.1080/00365590801943274 | s2cid = 38638336 | url = }}</ref>

==See also==
* [[Scandinavian Prostate Cancer Group]]
* [[Prostate Adenocarcinoma: TransCutaneous Hormones]]

==References==
{{Reflist}}


[[Category:Clinical trial organizations]]
[[Category:Evidence-based medicine]]
[[Category:Prostate cancer]]
[[Category:Scientific organisations based in Finland]]